Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a

Cancer Letters

Volumn 381, Issue 2, 2016, Pages 359-369

  Jia, Peng ^a   Cai, Heng ^a,b   Liu, Xiaobai ^a,b   Chen, Jiajia ^a   Ma, Jun ^a   Wang, Ping ^a   Liu, Yunhui ^a,b   Zheng, Jian ^a,b   Xue, Yixue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Liaoning Province Oral Diseases Translation Medcicne Research Center   (China)

Author keywords

Glioma; H19; MicroRNA 29a; Vascular endothelial cell; VASH2

Indexed keywords

ANGIOGENIC FACTOR; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA H19; MICRORNA 29A; UNCLASSIFIED DRUG; VASOHIBIN 2; 3' UNTRANSLATED REGION; ANGIOGENIC PROTEIN; H19 LONG NON-CODING RNA; MICRORNA; MIRN29 MICRORNA, HUMAN; VASH2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; MICROVASCULATURE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUBE FORMATION; UPREGULATION; VASCULAR ENDOTHELIAL CELL; BINDING SITE; BIOLOGY; BRAIN TUMOR; CELL MOTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VASCULARIZATION;

3' UNTRANSLATED REGIONS; ANGIOGENIC PROTEINS; BINDING SITES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; RNA INTERFERENCE; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84989938308     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.08.009     Document Type: Article

References (47)

1. [1] Khasraw, M., Ameratunga, M.S., Grant, R., Wheeler, H., Pavlakis, N., Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst. Rev(9), 2014 CD008218.
2. [2] Wang, J., Su, H.K., Zhao, H.F., Chen, Z.P., To, S.S., Progress in the application of molecular biomarkers in gliomas. Biochem. Biophys. Res. Commun 465 (2015), 1–4.
3. [3] Chi, A.S., Sorensen, A.G., Jain, R.K., Batchelor, T.T., Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14 (2009), 621–636.
4. [4] Sharma, R.A., Harris, A.L., Dalgleish, A.G., Steward, W.P., O'Byrne, K.J., Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2 (2001), 726–732.
5. [5] Ueda, Y., Nakagawa, T., Kubota, T., Ido, K., Sato, K., Glioma cells under hypoxic conditions block the brain microvascular endothelial cell death induced by serum starvation. J. Neurochem 95 (2005), 99–110.
6. [6] Yuan, B., Xian, R., Ma, J., Chen, Y., Lin, C., Song, Y., Isthmin inhibits glioma growth through antiangiogenesis in vivo. J. Neurooncol 109 (2012), 245–252.
7. [7] Rahman, R., Smith, S., Rahman, C., Grundy, R., Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J. Oncol, 2010, 2010, 251231.
8. [8] Virrey, J.J., Golden, E.B., Sivakumar, W., Wang, W., Pen, L., Schonthal, A.H., et al. Glioma-associated endothelial cells are chemoresistant to temozolomide. J. Neurooncol 95 (2009), 13–22.
9. [9] Marshall, L., White, R.J., Non-coding RNA production by RNA polymerase III is implicated in cancer. Nat. Rev. Cancer 8 (2008), 911–914.
10. [10] Patel, J.S., Hu, M., Sinha, G., Walker, N.D., Sherman, L.S., Gallagher, A., et al. Non-coding RNA as mediators in microenvironment-breast cancer cell communication. Cancer Lett 380 (2016), 289–295.
11. [11] Ling, H., Fabbri, M., Calin, G.A., MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov 12 (2013), 847–865.
12. [12] Zhang, K., Sun, X., Zhou, X., Han, L., Chen, L., Shi, Z., et al. Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget 6 (2015), 537–546.
13. [13] Wang, Q., Zhang, J., Liu, Y., Zhang, W., Zhou, J., Duan, R., et al. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett 373 (2016), 251–259.
14. [14] Zhang, X., Sun, S., Pu, J.K., Tsang, A.C., Lee, D., Man, V.O., et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol. Dis 48 (2012), 1–8.
15. [15] Liu, X.H., Sun, M., Nie, F.Q., Ge, Y.B., Zhang, E.B., Yin, D.D., et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol. Cancer, 13, 2014, 92.
16. [16] Cesana, M., Cacchiarelli, D., Legnini, I., Santini, T., Sthandier, O., Chinappi, M., et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147 (2011), 358–369.
17. [17] Court, F., Baniol, M., Hagege, H., Petit, J.S., Lelay-Taha, M.N., Carbonell, F., et al. Long-range chromatin interactions at the mouse Igf2/H19 locus reveal a novel paternally expressed long non-coding RNA. Nucleic Acids Res 39 (2011), 5893–5906.
18. [18] Zeira, E., Abramovitch, R., Meir, K., Even, R.S., Gil, Y., Bulvik, B., et al. The knockdown of H19lncRNA reveals its regulatory role in pluripotency and tumorigenesis of human embryonic carcinoma cells. Oncotarget 6 (2015), 34691–34703.
19. [19] Jiang, Y.J., Bikle, D.D., LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J. Steroid Biochem. Mol. Biol 144:Pt A (2014), 87–90.
20. [20] Qiu, M.T., Hu, J.W., Yin, R., Xu, L., Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol 34 (2013), 613–620.
21. [21] Shi, Y., Wang, Y., Luan, W., Wang, P., Tao, T., Zhang, J., et al. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS ONE, 9, 2014 e86295.
22. [22] Li, W., Jiang, P., Sun, X., Xu, S., Ma, X., Zhan, R., Suppressing H19 modulates tumorigenicity and stemness in U251 and U87MG glioma cells. Cell. Mol. Neurobiol, 2016, 10.1007/s10571-015-0320-5.
23. [23] Zhang, W., Mojsilovic-Petrovic, J., Andrade, M.F., Zhang, H., Ball, M., Stanimirovic, D.B., The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17 (2003), 2085–2087.
24. [24] Ma, J., Wang, P., Yao, Y., Liu, Y., Li, Z., Liu, X., et al. Knockdown of long non-coding RNA MALAT1 increases the blood-tumor barrier permeability by up-regulating miR-140. Biochim. Biophys. Acta 2016 (1859), 324–338.
25. [25] Wurdinger, T., Tannous, B.A., Saydam, O., Skog, J., Grau, S., Soutschek, J., et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14 (2008), 382–393.
26. [26] Xu, K., Gao, H., Shu, H.K., Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis. Mol. Cancer Ther 10 (2011), 138–147.
27. [27] Luo, M., Li, Z., Wang, W., Zeng, Y., Liu, Z., Qiu, J., Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 333 (2013), 213–221.
28. [28] Li, H., Yu, B., Li, J., Su, L., Yan, M., Zhu, Z., et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5 (2014), 2318–2329.
29. [29] Vennin, C., Spruyt, N., Dahmani, F., Julien, S., Bertucci, F., Finetti, P., et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget 6 (2015), 29209–29223.
30. [30] Yoshimizu, T., Miroglio, A., Ripoche, M.A., Gabory, A., Vernucci, M., Riccio, A., et al. The H19 locus acts in vivo as a tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 12417–12422.
31. [31] Nakagawa, H., Chadwick, R.B., Peltomaki, P., Plass, C., Nakamura, Y., de La Chapelle, A., Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 591–596.
32. [32] Hibi, K., Nakamura, H., Hirai, A., Fujikake, Y., Kasai, Y., Akiyama, S., et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 56 (1996), 480–482.
33. [33] Jiang, X., Yan, Y., Hu, M., Chen, X., Wang, Y., Dai, Y., et al. Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells. J. Neurosurg 124 (2016), 129–136.
34. [34] Voellenkle, C., Garcia-Manteiga, J.M., Pedrotti, S., Perfetti, A., De Toma, I., Da, S.D., et al. Implication of long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. Sci. Rep, 6, 2016, 24141.
35. [35] Conigliaro, A., Costa, V., Lo, D.A., Saieva, L., Buccheri, S., Dieli, F., et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol. Cancer, 14, 2015, 155.
36. [36] Dey, B.K., Pfeifer, K., Dutta, A., The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev 28 (2014), 491–501.
37. [37] Keniry, A., Oxley, D., Monnier, P., Kyba, M., Dandolo, L., Smits, G., et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell Biol 14 (2012), 659–665.
38. [38] Wang, J., Liu, X., Wu, H., Ni, P., Gu, Z., Qiao, Y., et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38 (2010), 5366–5383.
39. [39] Cai, H., Xue, Y., Wang, P., Wang, Z., Li, Z., Hu, Y., et al. The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. Oncotarget 6 (2015), 19759–19779.
40. [40] Kallen, A.N., Zhou, X.B., Xu, J., Qiao, C., Ma, J., Yan, L., et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol. Cell 52 (2013), 101–112.
41. [41] Liu, L., Yang, J., Zhu, X., Li, D., Lv, Z., Zhang, X., Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J. 283 (2016), 2326–2339.
42. [42] Gebeshuber, C.A., Zatloukal, K., Martinez, J., miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10 (2009), 400–405.
43. [43] Chen, L., Xiao, H., Wang, Z.H., Huang, Y., Liu, Z.P., Ren, H., et al. miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep 47 (2014), 39–44.
44. [44] Wu, J., Li, L., Jiang, C., Identification and evaluation of serum microRNA-29 family for glioma screening. Mol. Neurobiol 52 (2015), 1540–1546.
45. [45] Zhao, D., Jiang, X., Yao, C., Zhang, L., Liu, H., Xia, H., et al. Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion. J. Neurooncol 118 (2014), 39–47.
46. [46] Xue, X., Gao, W., Sun, B., Xu, Y., Han, B., Wang, F., et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 32 (2013), 1724–1734.
47. [47] Takahashi, Y., Koyanagi, T., Suzuki, Y., Saga, Y., Kanomata, N., Moriya, T., et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol. Cancer Res 10 (2012), 1135–1146.